Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 139

1.

Long-term effects of alogliptin benzoate in hemodialysis patients with diabetes: a 2-year study.

Nakamura Y, Inagaki M, Shimizu T, Fujita K, Inoue M, Gotoh H, Oguchi K, Goto Y.

Nephron Clin Pract. 2013;123(1-2):46-51. doi: 10.1159/000351678. Epub 2013 Jun 11.

PMID:
23774306
2.

The dipeptidyl peptidase-4 inhibitor alogliptin improves glycemic control in type 2 diabetic patients undergoing hemodialysis.

Fujii Y, Abe M, Higuchi T, Mizuno M, Suzuki H, Matsumoto S, Ito M, Maruyama N, Okada K, Soma M.

Expert Opin Pharmacother. 2013 Feb;14(3):259-67. doi: 10.1517/14656566.2013.761690. Epub 2013 Jan 7.

PMID:
23289982
3.

Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label long-term extension study.

Kaku K, Itayasu T, Hiroi S, Hirayama M, Seino Y.

Diabetes Obes Metab. 2011 Nov;13(11):1028-35. doi: 10.1111/j.1463-1326.2011.01460.x.

PMID:
21682833
4.

Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double-blind, randomized, 1-year study.

Rosenstock J, Wilson C, Fleck P.

Diabetes Obes Metab. 2013 Oct;15(10):906-14. doi: 10.1111/dom.12102. Epub 2013 Apr 18.

PMID:
23531118
5.

Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.

Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.

Br J Pharmacol. 2009 Jun;157(3):415-26. doi: 10.1111/j.1476-5381.2009.00145.x. Epub 2009 Apr 3.

6.

Alogliptin: a new dipeptidyl peptidase-4 inhibitor for type 2 diabetes mellitus.

Jarvis CI, Cabrera A, Charron D.

Ann Pharmacother. 2013 Nov;47(11):1532-9. doi: 10.1177/1060028013504076. Review.

PMID:
24285765
7.

Alogliptin: safety, efficacy, and clinical implications.

Marino AB, Cole SW.

J Pharm Pract. 2015 Feb;28(1):99-106. doi: 10.1177/0897190014522063. Epub 2014 Feb 13. Review.

PMID:
24532820
8.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy.

Pratley RE, Kipnes MS, Fleck PR, Wilson C, Mekki Q; Alogliptin Study 007 Group..

Diabetes Obes Metab. 2009 Feb;11(2):167-76. doi: 10.1111/j.1463-1326.2008.01016.x.

PMID:
19125778
9.

Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies.

Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q.

J Am Geriatr Soc. 2009 Nov;57(11):2011-9. doi: 10.1111/j.1532-5415.2009.02484.x. Epub 2009 Sep 30.

PMID:
19793357
10.

Alogliptin as an initial therapy in patients with newly diagnosed, drug naïve type 2 diabetes: a randomized, control trial.

Kutoh E, Ukai Y.

Endocrine. 2012 Jun;41(3):435-41. doi: 10.1007/s12020-012-9596-0. Epub 2012 Jan 17.

PMID:
22249941
11.

The Beneficial Effects of the DPP-4 Inhibitor Alogliptin on Hemoglobin A1c and Serum Lipids in Japanese Patients with Type 2 Diabetes.

Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T.

Drug Res (Stuttg). 2016 Jan;66(1):18-22. doi: 10.1055/s-0035-1547254. Epub 2015 Jun 30.

PMID:
26125284
12.

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study.

Pratley RE, Reusch JE, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 009 Group..

Curr Med Res Opin. 2009 Oct;25(10):2361-71. doi: 10.1185/03007990903156111.

PMID:
19650752
13.

Anti-inflammatory effects of linagliptin in hemodialysis patients with diabetes.

Nakamura Y, Tsuji M, Hasegawa H, Kimura K, Fujita K, Inoue M, Shimizu T, Gotoh H, Goto Y, Inagaki M, Oguchi K.

Hemodial Int. 2014 Apr;18(2):433-42. doi: 10.1111/hdi.12127. Epub 2014 Jan 10.

PMID:
24405885
14.

Glycemic control after addition of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes showing inadequate response to thrice-a-day treatment with α-glucosidase inhibitors.

Masuda K, Aoki K, Kamiko K, Takihata M, Ito Y, Nagakura M, Kawasaki S, Akema N, Hasegawa M, Nakajima S, Shinoda K, Toumura S, Tsunoda S, Enomoto H, Shimotomai H, Terauchi Y.

Expert Opin Pharmacother. 2013 Jun;14(9):1111-8. doi: 10.1517/14656566.2013.790365. Epub 2013 Apr 22. Erratum in: Expert Opin Pharmacother. 2013 Jul;14(10):1429.

PMID:
23600363
15.

Chronic administration of alogliptin, a novel, potent, and highly selective dipeptidyl peptidase-4 inhibitor, improves glycemic control and beta-cell function in obese diabetic ob/ob mice.

Moritoh Y, Takeuchi K, Asakawa T, Kataoka O, Odaka H.

Eur J Pharmacol. 2008 Jul 7;588(2-3):325-32. doi: 10.1016/j.ejphar.2008.04.018. Epub 2008 Apr 10.

PMID:
18499100
16.

Effects of alogliptin in chronic kidney disease patients with type 2 diabetes.

Sakai Y, Suzuki A, Mugishima K, Sumi Y, Otsuka Y, Otsuka T, Ohno D, Murasawa T, Tsuruoka S.

Intern Med. 2014;53(3):195-203.

17.

[Alogliptin (Vipidia): a selective DPP-4 inhibitor with a good cardiovascular safety].

Scheen AJ.

Rev Med Liege. 2014 Jul-Aug;69(7-8):460-6. Review. French.

18.

Efficacy and safety of alogliptin added to metformin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled trial with an open-label, long-term extension study.

Seino Y, Miyata Y, Hiroi S, Hirayama M, Kaku K.

Diabetes Obes Metab. 2012 Oct;14(10):927-36. doi: 10.1111/j.1463-1326.2012.01620.x. Epub 2012 Jun 5.

PMID:
22583697
19.

Effect of combination therapy with alogliptin and lansoprazole on glycemic control in patients with type 2 diabetes.

Takebayashi K, Sakurai S, Suzuki T, Hori K, Terasawa T, Naruse R, Hara K, Suetsugu M, Tsuchiya T, Aoki H, Hamasaki T, Shuutou H, Inukai T.

Endocr J. 2014;61(10):1031-9. Epub 2014 Sep 2.

20.

[Alogliptin].

Tanabe A, Kaku K.

Nihon Rinsho. 2011 May;69(5):871-6. Review. Japanese.

PMID:
21595274

Supplemental Content

Support Center